A randomized lifestyle intervention with 5-year follow-up in subjects with impaired glucose tolerance: Pronounced short-term impact but long-term adherence problems

Scandinavian Journal of Public Health

Volumn 37, Issue 4, 2009, Pages 434-442

  Lindahl, Bernt ^a   Söderberg, Stefan ^a   Widman, Lars ^a   Johnson, Owe ^a   Hallmans, Göran ^a   Jansson, Jan Håkan ^a   Nilssön, Torbjörn K ^b   Borch Johnsen, Knut ^c   Røder, Michael E ^d  

^a UMEÅ UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c STENO DIABETES CENTER   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

Author keywords

Cardiovascular risk factors; diabetes mellitus; diet; intervention; physical activity

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SWEDEN;

EID: 66849118860     PISSN: 14034948     EISSN: None     Source Type: Journal    
DOI: 10.1177/1403494808101373     Document Type: Article

References (24)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
2. Norhammar A., Tenerz Å., Nilsson G., Hamsten A., Efendic S., Rydén L., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.
3. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-332.
4. Frayn K.N., Karpe F., Fielding B.A., Macdonald I.A., Coppack S.W. Integrative physiology of human adipose tissue. Int J Öbes 2003;27:875-888.
5. Kilander L., Berglund L., Boberg M., Vessby B., Lithell H. Education, lifestyle factors and mortality from cardiovascular disease and cancer. A 25-year follow-up of Swedish 50-year-old men. Int J Epidemiol 2001;30:1119-1126.
6. Anderson A.S. Nutrition interventions in women in low-income groups in the UK. Proc Nutr Soc 2007;66:25-32.
7. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Lanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
8. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
9. Ruge T., Nyström L., Lindahl B., Hallmans G., Norberg M., Weinehall L., et al. Recruiting high-risk individuals to a diabetes prevention program. How hard can it be? Diabetes Care 2007;30:e61.
10. Weinehall L., Westman G., Hellsten G., Boman K., Hallmans G., Pearson T.A., et al. Shifting the distribution of risk: results of a community intervention in a Swedish programme for the prevention of cardiovascular disease. J Epidemiol Community Health 1999;53:243-250.
11. Lindahl B., Nilsson T.K., Jansson J.-H., Asplund K., Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med 1999;246:105-112.
12. Johansson I., Hallmans G., Wikman A., Biessy C., Riboli E., Kaaks R. Validation and calibration of food-frequency questionnaire measurements in the Northern Sweden Health and Disease cohort. Public Health Nutr 2002; 5:487-496.
13. WHÖ Expert Committee on Diabetes Mellitus. Technical report series 727. Geneva: World Health Örganization, 1985.
14. Andersen L., Dinesen B., Jorgensen P.N., Poulsen F., Roder M.E. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-582.
15. Kjems L.L., Roder M.E., Dinesen B., Hartling S.G., Jorgensen P.N., Binder C. Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 1993; 39:2146-2150.
16. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HÖMA modeling. Diabetes Care 2004;27:1487-1495.
17. Chmielewska J., Rånby M., Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31:427-436.
18. Cejka J. An enzyme-linked immunoassay for von Willebrand factor. Clin Chem 1982;32:1132-5.
19. Öster G., Thompson D., Edelsberg J., Bird A.P., Colditz G.A. Lifetime health and economic benefits of weight loss among obese persons. Am J Public Health 1999;89:1536-1542.
20. Vidal J. Updated review on the benefits of weight loss. Int J Öbes 2002;26 Suppl 4:S25-S28.
21. Hämäläinen H., Rönnemaa T., Virtanen A., Lindström J., Eriksson J.G., Valle T.T., et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 2005; 48:2248-2253.
22. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-1572.
23. Lindström J., Lanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemiö K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9.
24. Rothwell P.M. External validity of randomised controlled trials: ‘To whom do the results of this trial apply?’. Lancet 2005;365:82-93.